- Home
- Publications
- Publication Search
- Publication Details
Title
The Alzheimer’s disease drug development landscape
Authors
Keywords
-
Journal
Alzheimers Research & Therapy
Volume 13, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-11-11
DOI
10.1186/s13195-021-00927-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Alzheimer's disease
- (2021) Philip Scheltens et al. LANCET
- A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody
- (2021) Chad J. Swanson et al. Alzheimers Research & Therapy
- The multiplex model of the genetics of Alzheimer’s disease
- (2020) Rebecca Sims et al. NATURE NEUROSCIENCE
- A Path Toward Precision Medicine for Neuroinflammatory Mechanisms in Alzheimer's Disease
- (2020) Harald Hampel et al. Frontiers in Immunology
- Cognitive outcomes in trials of two BACE inhibitors in Alzheimer's disease
- (2020) Alette M. Wessels et al. Alzheimers & Dementia
- Immune response and endocytosis pathways are associated with the resilience against Alzheimer’s disease
- (2020) Niccolò Tesi et al. Translational Psychiatry
- Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer’s disease risk
- (2019) Iris E. Jansen et al. NATURE GENETICS
- The Pharmaceutical Industry in 2018. An Analysis of FDA Drug Approvals from the Perspective of Molecules
- (2019) Beatriz G. de la Torre et al. MOLECULES
- Cholesterol Metabolism Is a Druggable Axis that Independently Regulates Tau and Amyloid-β in iPSC-Derived Alzheimer’s Disease Neurons
- (2019) Rik van der Kant et al. Cell Stem Cell
- Current and emerging avenues for Alzheimer's disease drug targets
- (2019) R. Loera‐Valencia et al. JOURNAL OF INTERNAL MEDICINE
- The “rights” of precision drug development for Alzheimer’s disease
- (2019) Jeffrey Cummings et al. Alzheimers Research & Therapy
- Global, regional, and national burden of Alzheimer's disease and other dementias, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016
- (2018) Emma Nichols et al. LANCET NEUROLOGY
- Clinical trial transparency: a reassessment of industry compliance with clinical trial registration and reporting requirements in the United States
- (2017) Scott M Lassman et al. BMJ Open
- Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer’s disease
- (2016) Rik Ossenkoppele et al. BRAIN
- The Cellular Phase of Alzheimer’s Disease
- (2016) Bart De Strooper et al. CELL
- The impact of low-frequency and rare variants on lipid levels
- (2015) Ida Surakka et al. NATURE GENETICS
- Increased expression of BIN1 mediates Alzheimer genetic risk by modulating tau pathology
- (2013) J Chapuis et al. MOLECULAR PSYCHIATRY
- Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease
- (2013) Jean-Charles Lambert et al. NATURE GENETICS
- Common Alzheimer’s Disease Research Ontology: National Institute on Aging and Alzheimer’s Association Collaborative Project
- (2012) Lorenzo M. Refolo et al. Alzheimers & Dementia
- Role of Phosphatidylinositol Clathrin Assembly Lymphoid-Myeloid Leukemia (PICALM) in Intracellular Amyloid Precursor Protein (APP) Processing and Amyloid Plaque Pathogenesis
- (2012) Qingli Xiao et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Drug discovery: new models for industry–academic partnerships
- (2008) Cathy J. Tralau-Stewart et al. DRUG DISCOVERY TODAY
- Common and rare variants in multifactorial susceptibility to common diseases
- (2008) Walter Bodmer et al. NATURE GENETICS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now